Ramucirumab heads straight for the lock itself—VEGFR-2—and sits right in it, acting as a surgical strike against the tumor's ability to feed itself by plugging the master lock on its infrastructure project.
How ramucirumab works and why it's different


Ramucirumab, also known by the brand name Cyramza, is a fully human monoclonal antibody that functions as a VEGFR2 antagonist. It specifically binds to the Vascular Endothelial Growth Factor Receptor 2, blocking the binding of VEGF ligands. By preventing this interaction, the drug inhibits the signaling pathways that trigger the growth of new blood vessels, a process essential for tumor progression and survival.
While many angiogenesis inhibitors target the VEGF ligands themselves, ramucirumab is different because it directly targets the VEGFR2 receptor. This specific mechanism of action allows it to block the activation of the receptor more directly than drugs that only neutralize circulating proteins. As a targeted monoclonal antibody, it provides a precise approach to disrupting the blood supply that tumors need to grow and spread.
Ramucirumab is often discussed within the broader context of advanced cancer treatments and monoclonal antibodies. While its primary function is as an angiogenesis inhibitor rather than a traditional checkpoint inhibitor, it plays a critical role in modern oncology. By altering the tumor microenvironment and restricting blood vessel formation, it works alongside other therapies to improve outcomes for patients undergoing treatment for various types of solid tumors.
From Columbia University alumni built in San Francisco
"Instead of endless scrolling, I just hit play on BeFreed. It saves me so much time."
"I never knew where to start with nonfiction—BeFreed’s book lists turned into podcasts gave me a clear path."
"Perfect balance between learning and entertainment. Finished ‘Thinking, Fast and Slow’ on my commute this week."
"Crazy how much I learned while walking the dog. BeFreed = small habits → big gains."
"Reading used to feel like a chore. Now it’s just part of my lifestyle."
"Feels effortless compared to reading. I’ve finished 6 books this month already."
"BeFreed turned my guilty doomscrolling into something that feels productive and inspiring."
"BeFreed turned my commute into learning time. 20-min podcasts are perfect for finishing books I never had time for."
"BeFreed replaced my podcast queue. Imagine Spotify for books — that’s it. 🙌"
"It is great for me to learn something from the book without reading it."
"The themed book list podcasts help me connect ideas across authors—like a guided audio journey."
"Makes me feel smarter every time before going to work"
From Columbia University alumni built in San Francisco
